What one share of Jyong Biotech holds
We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public.
Jyong Biotech’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.06 |
|---|---|
| Cash and investments | $0.02 |
| Debt | $0.23 |
| Book value | −$0.33 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$0.06 | — | — | — | −$0.48 |
| 2024 | — | −$0.04 | — | — | — | −$0.50 |
| 2025 | — | −$0.06 | — | — | — | −$0.33 |
Common questions about Jyong Biotech
How much does one share of Jyong Biotech earn?
Over its latest fiscal year, Jyong Biotech lost $0.06 for each share.
Does Jyong Biotech pay a dividend?
Jyong Biotech didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Jyong Biotech’s book value per share?
Jyong Biotech’s book value is negative (−$0.33 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of December 31, 2025.
How much cash and debt does each share of Jyong Biotech have?
Each share of Jyong Biotech has $0.02 of cash and investments and $0.23 of debt, as of December 31, 2025.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.